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Abstract
Background: To assess the association between maternal human immunodeficiency virus (HIV) infection and low
birth weight (LBW)/prematurity (PTD), we conducted a meta-analysis of cohort studies of HIV infected and
uninfected women.
Methods: Several English and Chinese databases were searched (updated to May 2015) to find the studies
reporting infant outcomes associated with exposure to maternal HIV infection during pregnancy. Relevant articles
were manually selected based on several inclusion and exclusion criteria.
Results: Fifty-two cohort studies including 15,538 (for LBW) and 200,896 (for PTD) HIV infected women met the
inclusion criteria. There was significant heterogeneity among studies for maternal HIV infection associated with
LBW/PTD (I2 = 71.7 %, P < 0.05, and I2 = 51.8 %, P < 0.05 for LBW and PTD, respectively). The meta-analysis
demonstrated that the maternal HIV infection was significantly associated with both LBW (pooled odds ratio (OR):
1.73, 95 % confidence interval (CI): 1.64, 1.82, P < 0.001) and PTD (pooled OR: 1.56, 95 % CI: 1.49, 1.63, P < 0.001). No
significant difference in the relationship between maternal HIV infection and adverse pregnancy outcomes was
detected among the groups of different study periods. HIV infected women were at slightly higher risk of LBW in
developing countries compared with women in developed countries (OR: 2.12 (95 % CI: 1.81, 2.48) vs. 1.75 (95 % CI:
1.44, 2.12)). Antiretroviral drugs usage did not significantly change the associations of maternal HIV exposure with
LBW and PTD.
Conclusions: HIV infected women were at higher risk of having a low birth weight infant or a preterm delivery
infant compared with uninfected women. Such associations did not change significantly over time or were not
significantly affected by the usage of antiretroviral drugs.
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Background
Although new infections of human immunodeficiency
virus (HIV) show a descending trend in recent years, the
number of people living with HIV has been rising year
by year. More than 16 million (95 % CI: 14.8 million,
17.4 million) female adults had been infected with HIV
by the end of 2012 [1]. There is a risk for mother-to-
child transmission of HIV. Among HIV infected women
who took the highly active antiretroviral therapy
(HAART), studies reported that the mother-to-child
transmission (MTCT) rate ranged from 1 to 5 % [2], and
it was around 10 % among women who did not [3, 4].
There is also a possibility that maternal HIV infec-
tion has severe impacts on pregnancy outcomes. It
has been reported that HIV infected women are
more likely to encounter adverse pregnancy out-
comes, such as low birth weight (LBW) and preterm
delivery (PTD) [5]. And it is suggested that LBW
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and PTD are important risk factors for post-neonatal
mortality and morbidity and other adverse events in-
cluding neurodevelopmental problems [6, 7].
Studies have provided inconsistent results for the asso-
ciation between maternal HIV infection and LBW/PTD.
Some studies suggested that maternal HIV infection
could increase the risk of LBW and PTD [8–10], but
others reported no significant association between them
[11–13]. Brocklehurst et al. [5] summarized the study re-
sults published between 1983 and 1996. They found the
association of maternal HIV infection with adverse preg-
nancy outcomes such as LBW and PTD, but failed to
assess the effect of antiretroviral drugs on it. There have
been many new studies on the association between
maternal HIV infection and adverse pregnancy outcomes
reported in the past 20 years. For this reason, we con-
ducted a meta-analysis to provide an update on the rela-
tionship between maternal HIV infection and LBW/PTD.
In addition, there has been a rapid progress of medication
and heath care for HIV infected women, and we assessed
the influence of such a progress on the relationship.
Methods
Search strategy
We searched English databases (EMBASE, MEDLINE via
PubMed and Web of Science) and Chinese databases
(China National Knowledge Infrastructure, Wan Fang
database, Sino Med and VIP) up to May 31, 2015 for stud-
ies reporting infant outcomes among women exposed and
unexposed to HIV infection during pregnancy. Articles
were searched using the following search terms: “maternal
HIV infection” “HIV infected mothers/HIV infected preg-
nant women” combined with “pregnant outcomes/birth
outcomes” “low birth weight (LBW)” “prematurity/pre-
term birth/preterm delivery (PTD)”. Only cohort studies
were included.
Study selection
The relevant articles were manually selected based on
the following criteria: (1) Types of studies: Prospective
or retrospective cohort studies; unsystematic observa-
tions (case series or case reports) were excluded from all
analyses. Because cohort studies demonstrate strong in-
tensity compared with other observational studies in
terms of causality. (2) Types of participants: Women
with HIV infection during pregnancy. (3) Types of com-
parators: Women with no HIV infection during preg-
nancy. (4) Types of pregnancy outcomes: LBW (defined as
birth weight <2500 g) and PTD (defined as gestational age
<37 weeks). (5) All the articles reported or allowed the
calculation of odd ratios (OR) with corresponding 95 %
confidence intervals (95 % CIs). In order to standardize
the results, all measures of effect were expressed as OR
and 95 % CIs. (6) Published in English or Chinese, and full
text was available. When the same cohort population was
used in several papers, only the most recent ones were in-
cluded in the current analysis, i.e., the same study data
were only used once in the study.
Assessment of study quality and data extraction
We adapted the Newcastle-Ottawa Scale suggested by
Zeng et al. [14] to measure study quality. Scores were
awarded for each criterion met, and the maximum score
was 9. Studies were graded high quality if the score was
no less than 7 and low quality if the score was under 7.
Abstracts and conference papers were graded 0 for quality
and were included in the low quality category for sensitiv-
ity analyses.
Two researchers selected literature in accordance with
the inclusion and exclusion criteria, and extracted data
after independent verification. The following information
was extracted from each study: subject of the literature,
the author, year of publication,location of the study
population, number of women in the two groups, odds
ratio and its 95 % CIs for LBW and PTD associated with
maternal HIV infection, exposure to maternal use of
antiretroviral drugs before or during pregnancy.
Statistical analysis
Stata12.0 software was used to analyze the data. For both
LBW and PTD, if no significant heterogeneity for their
associations with maternal HIV exposure among the
studies included was found (P > 0.1, I2 < 50 %), a fixed
effect model was used to calculate ORs and their 95 %
CIs. Otherwise,a random effects model was used. The
sensitivity of data was analyzed by using the method
which reduced the biggest weight of literature. Funnel
plot and the Egger’s linear regression method were used
to assess publication bias.
No ethics statement to declare.
Results
Articles included in the Meta-analysis and study select
process
A total of 1148 articles were identified. After removing
duplicate publications and based on our inclusion and
exclusion criteria, 52 articles were included in our ana-
lysis (Table 1, Fig. 1) and of them, 43 were related to
LBW and 40 were related to PTD. They were all pub-
lished in English. More than 60 % of the articles were
conducted in Africa (n = 24) and America (n = 11), and 8
were from Europe (n = 2) and Asia (n = 6).
The prevalence of infants born before 37 weeks’ gesta-
tion ranged from 5.2 to 73.0 % in HIV infected women
and 2.2 to 32 % in HIV uninfected women. The preva-
lence of LBW among HIV infected women ranged from
3.4 to 56.0 % and 2.5 to 36.9 % in HIV uninfected
women. Odds ratios for the association of HIV exposure
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Table 1 Characteristics of the included studies
First author, publication year Study year Design type Study
location
Low birth weight Preterm delivery Qa Confounding Exposure
to ARVs*Number of
infected women
Rate OR Number of
infected women
Rate OR
Hira et al., 1989 [30] 1987 Prospective Zambia 227 9.7 3.75 227 6.6 1.37 5 No No
Lallemant et al., 1989 [31] 1987–1988 Prospective Congo 64 26.0 3.22 3 No No
Selwyn et al., 1989 [32] 1989 Prospective USA 25 32.0 1.01 0 No No
Braddick et al., 1990 [33] 1986–1989 Retrospective Malawi 167 9.0 3.00 165 16.0 1.50 7 No No
Semprini et al., 1990 [34] 1985- Prospective Italy 74 15.0 0.42 5 No No
Halsey et al., 1990 [35] 1976–1985 Prospective Haiti 199 18.6 1.78 199 6.9 3.35 0 No No
Lepage et al., 1991 [36] 1988–1989 Prospective Rwanda 218 17.2 1.40 9 No No
Mayers et al., 1991 [37] 1985–1989 Prospective USA 33 36.0 1.76 6 No No
Alger et al., 1993 [38] 1987–1991 Prospective USA 101 27.7 1.05 0 No No
St Louis et al., 1993 [39] 1989–1990 Prospective Congo 324 20.4 1.31 0 No Not
Bulterys et al., 1994 [40] 1989–1992 Prospective Rwanda 274 7.8 1.79 297 28.0 1.50 9 No No
Temmerman et al., 1994 [8] 1989–1991 Prospective Kenya 285 19.6 1.40 315 24.1 1.90 9 No No
Taha et al., 1995 [41] before 1995 Prospective Malawi 663 20.1 2.55 7 No Not stated
Kumar et al., 1995 [42] 1992–1993 Prospective India 150 21.6 2.12 150 22.0 3.29 9 No Not stated
Mauri et al., 1995 [43] 1986–1992 Prospective Italy 38 16.0 1.91 7 No Not stated
Bloland et al., 1995 [44] 1987–1990 Prospective Malawi 92 17.4 1.76 85 6.5 1.51 9 No No
Markson et al., 1996 [45] 1989–1990 Prospective USA 772 29.0 2.04 7 Yes Not stated
Bucceri et al., 1997 [11] 1985–1993 Prospective Italy 153 32.0 1.20 151 21.0 0.90 3 No Not stated
Castetbon et al., 1999 [46] 1992–1993 Prospective Rwanda 177 18.6 2.24 177 21.5 2.03 9 Yes, LBW: aOR = 1.21
(0.58–2.56)
Not stated
Coley et al., 2001 [12] 1995–1997 Prospective Tanzania 433 15.2 1.25 420 27.1 1.11 7 Yes, aOR =1.21 and
1.11for LBW and PTD
Not stated








Friis et al., 2004 [48] 1996–1997 Retrospective Zimbabwe 360 14.7 1.74 360 21.1 1.46 9 Not mentioned Not stated
van Eijk et al., 2004 [49] 1996–2000 Retrospective Kenya 641 4.8 1.81 641 8.1 1.16 6 No Not stated
Boer et al., 2007 [50] 1997–2003 Retrospective Holland 142 17.0 1.72 143 18.0 2.24 4 Yes Yes
Schulte et al., 2007 [10] 1989–2004 [10] Retrospective USA 1744 26.0 1.45 1614 27.0 1.77 9 Yes, aOR = 1.34 for LBW














Table 1 Characteristics of the included studies (Continued)
Haeri et al., 2008 [51] before 2008 Retrospective USA 151 30.0 3.04 151 18.0 1.63 0 Yes (spontaneous PTD
aOR = 2.27 (1.2–4.3))
Yes
Mitgitti et al., 2008 [52] 1997–2002 Retrospective Thailand 266 12.0 1.78 247 8.5 1.23 7 Yes, LBW aOR = 1.98
(1.26–3.10)
Not stated
Habib et al., 2008 [53] 1999–2006 Retrospective Tanzania 434 10.4 1.25 5 Yes Yes, partly
Ezeaka et al., 2009 [54] 2002–2005 Prospective Nigeria 220 16.8 3.47 7 No Not stated
Uneke et al., 2009 [55] 2006 Prospective Nigeria 3 25.0 3.16 0 No Not stated
Musana et al., 2009 [56] 2004–2005 Prospective Kenya 68 56.0 2.80 68 73 2.20 3 No Not stated
Olagbuji et al., 2010 [57] 2007–2008 Prospective Nigeria 203 18.2 5.43 203 12.8 1.98 9 No Yes
Pattinson et al., 2010 [58] 2006–2008 Retrospective South Africa 3014 19.8 1.47 0 No Yes, partly
Patil et al., 2011 [13] 2002–2003 Prospective India 212 31.1 0.77 212 13.7 1.13 7 No Yes, partly
Asavapiriyanont et al., 2011 [59] 2004–2008 Prospective USA 420 12.6 0.94 0 Not mentioned Yes, partly
Ndirangu et al., 2012 [60] 2001–2004 Prospective South Africa 1189 9.8 1.48 1189 21.8 1.39 9 Yes, aOR for
PTD = 1.07
No
Lopez et al., 2012 [61] 1986–2010 Retrospective Spain 519 19.7 2.60 9 Yes, aOR = 2.5
(1.9–3.5)
Yes, partly
Chen et al., 2012 [62] 2009–2011 Retrospective Botswana 9504 23.7 1.50 4 Yes, aOR = 1.3
(1.3–1.4)
Yes
Nkhoma et al., 2012 [63] 2005–2006 Prospective Malawi 45 26.7 2.32 4 Yes, aOR = 3.08
(1.40–6.79)
Yes
Muhangi et al., 2013 [29] 2003–2005 Prospective Uganda 121 10.0 1.80 3 No Yes, only 5




Duan et al., 2014 [65] 2010–2013 Retrospective China 300 14.7 6.27 300 10.3 1.81 3 No Yes
He et al., 2013 [66] 2007–2009 Retrospective China 58 3.4 0.65 58 5.2 1.53 7 Yes
Wang et al., 2009 [67] 2007–2008 Retrospective China 35 14.3 3.55 3 No Yes
Han et al., 2004 [68] 1997–1999 Case control Tanzania 37 18.9 4.43 37 16.2 3.68 3 No Not stated
Dong et al., 2001 [69] 1995–1999 Case control Tanzania 86 16.3 2.40 86 14.0 3.08 3 No Not stated
Macdonald et al., 2015 [70] 2002–2003, 2010–2011 Retrospective Canada 615 12.5 1.90 615 14.6 1.76 7 Yes Yes
Salihu et al., 2013 [71] 1998–2007 Prospective USA 4634 1.73 4634 1.35 9 Yes Not stated
Boyajian et al., 2012 [72] 2003–2010 Retrospective Canada 91 20.2 2.91 91 15.6 1.70 7 Yes Yes
Brown et al., 2012 [73] 2000–2008 Retrospective USA 71 43.7 4.23 71 40.9 2.83 6 No Yes
Da Costa et al., 2013 [74] 1995–2005 Prospective Brazil 713 15.0 1.57 6 Yes, aOR 1.26
(0.90–1.770
Not stated
CI confidence interval, LBW low birth weight; OR odds ratio, aOR adjusted odds ratio, PTD preterm delivery













ranged from 0.65 to 6.27 with LBW and ranged from
0.42 to 3.68 with PTD.
Impact of maternal HIV infection on LBW and PTD
There was significant heterogeneity among studies for
maternal HIV infection associated with LBW/PTD (I2 =
71.7 %, P < 0.05, and I2 = 51.8 %, P < 0.05 for LBW and
PTD, respectively) suggesting that the summary mea-
sures need to be interpreted with caution. Pooled ORs
for LBW and PTD from random effect models were pre-
sented in Figs. 2 and 3, respectively. The summary OR
was 1.73 (95 % CI: 1.64, 1.82, P < 0.001) for LBW and
1.56 (95 % CI: 1.49, 1.63) for PTD, indicating that HIV
infected women had approximately 2-fold risk to deliver
low birth weight or preterm babies compared with unin-
fected ones.
Test for publication bias
Begg’s and Egger’s Tests suggested that there were sig-
nificant publication biases among the 43 studies of LBW
(Begg’s Test: z = 2.15, P = 0.03; Egger’s Test: t = 3.53,
P = 0.001) (Additional file 1). After adjusted by using
the Trim and Filling method, the pooled OR was 1.77
(95 % CI: 1.57, 2.00), which was near to the original
OR (1.73, 95 % CI: 1.64, 1.82). No significant publica-
tion bias was detected for the 40 articles of PTD (Begg’s
Test: z = 0.79, P = 0.43; Egger’s Test: t = 1.69, P = 0.10)
(Additional file 2).
Sensitivity analysis
After removing the article that counted the biggest
weight, there was no significant change of the results.
The pooled ORs were 1.98 (95 % CI: 1.76, 2.23) for LBW
and 1.62 (95 % CI: 1.49, 1.77) for PTD, respectively.
After stratified by location of study population, the sig-
nificant associations between maternal HIV infection
and LBW or PTD were still found in the studies from
Africa, America and Asia, except those from Europe.
Studies from Africa (OR = 2.18, 95 % CI: 1.84, 2.59),
America (OR = 1.80, 95 % CI: 1.49, 2.19) and Asia (OR =
1.99, 95 %CI: 1.05, 3.74) showed significant pooled ORs
for LBW, and for PTD the corresponding pooled ORs
were 1.56 (95 % CI: 1.40, 1.75), 1.69 (95 % CI: 1.53, 1.88)
and 1.60 (95 % CI: 1.10, 2.35), respectively. These associa-
tions were all significant in the two groups of developing
and developed countries. No significant difference in the
relationship was detected across study periods and their
pooled ORs were all statistically significant for both LBW
and PTD. But studies during 2005–2015 were at slightly
higher risk for both LBW and PTD compared with the
other two groups (Table 2).
We also conducted a subgroup analysis based on the
information of antiretroviral drugs (ARVs) usage. ARVs
usage before or during pregnancy did not decrease the
risks of both LBW and PTD. Women who took ARVs
were at similar risk of delivering low birth weight infants
(OR = 2.04, 95 % CI: 1.61, 2.57) compared with those did
not (OR = 1.75, 95 % CI: 1.42, 2.17). For PTD, the pooled
Fig. 1 Flow chart of study selection process
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ORs were 1.77 (95 CI: 1.55, 2.02) for women who took
drugs, 1.54 (95 % CI: 1.23, 1.92) for those who did not
took drug and 1.55 (95 % CI: 1.32, 1.82) for those who
provided no information about AVRs usage (Table 2).
Discussion
It has been previously reported that compared with un-
exposed children, children who encountered intrauterine
HIV exposure are more vulnerable to stunting, under-
weight and wasting, and their birth weight, height and
head circumference are generally lower than their unex-
posed counterparts [15]. However, it was controversial
for the effect of maternal HIV infection on both LBW
and PTD. Brocklehurst et al. [5] reported that the in-
creasing risks of LBW and PTD were associated with
maternal HIV infection. And they found that women in
Fig. 2 Forest plot of odds ratio for low birth weight. Pooled OR = 1.73, 95 % CI: 1.64, 1.82; Heterogeneity chi-squared = 148.65 (d.f. = 42), p = 0.000,
I-squared (variation in ES attributable to heterogeneity) = 71.7 %; Test of ES = 1: z = 20.06, p = 0.000
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developing countries had higher risks of both LBW and
PTD than those in developed countries. Our study,
which included a number of newer studies in the meta-
analysis also indicated that maternal HIV infection in-
creased the risks of both LBW and PTD. We found that
these associations were not affected by different study
periods or antiretroviral drugs usage. In addition, we did
not find marked difference in these associations between
developing and developed countries.
The HIV associated LBW and PTD might be related
to the damaged human immune system, especially the
reduced CD4+ T cells and immunosuppression. Previous
studies documented that women with CD4 cell counts
<350 cells/mm3 had an increased risk of having LBW
infants (RR = 1.57; 95 % CI: 1.16, 2.12) compared to
women with higher CD4 cell counts [16, 17]. There is a
possibility that women are immunocompromised during
pregnancy [18], and if accompanied with HIV infection,
Fig. 3 Forest plot of odds ratio for preterm delivery. Pooled OR = 1.56, 95 % CI: 1.49, 1.63; Heterogeneity chi-squared = 80.95 (d.f. = 39), p = 0.000,
I-squared (variation in ES attributable to heterogeneity) = 51.8 %; Test of ES = 1: z = 19.79, p = 0.000
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disease progress might be accelerated. Simultaneously,
reproductive tract infections, which are contributed to
the incidence of adverse pregnancy outcomes, would
occur more frequently due to the immunosuppression
[19]. Some studies have reported that HIV-1 can repli-
cate in the placenta [20], and it has also been shown that
HIV-1 infection may alter the cytokine profile in the pla-
centa [21, 22]. This may affect the function of placenta
during pregnancy, and then restrict the development of
fetal, which might be another incentive of LBW and PTD.
After stratified by antiretroviral drugs use before or
during pregnancy, we found that HAART or other regi-
mens of antiretroviral therapy (ART) had no obvious
effect on the associations between maternal HIV infec-
tion and LBW/PTD. It is suggested that intrauterine
ARVs exposure did not decrease or increase the risk of
LBW or PTD in HIV infected women. And this is con-
sistent with the findings reported by van der Merwe et
al. and Townsend et al. [3, 4]. However, Papp et al. [23]
suggested that Protease Inhibitor (PI)-based ART could
increase the risk of adverse pregnancy outcomes mainly
due to lower level of progesterone, which was signifi-
cantly associated with fetal weight. Sibude et al. [24] also
found that ARVs and, particularly, with the initiation of
ritonavir-boosted PI therapy during pregnancy were
correlated with PTD in HIV infected women. Though
we did not found such effect of ARVs on the association
between maternal HIV infection and LBW/PTD, no
details of information for AVRs and therapy regimens
may contribute to this. We found that studies during
2005–2015 were at slightly higher risk for both LBW
and PTD compared with the other two groups, it might
be related with the increasing use of combination ART
earlier in pregnancy, and more use of PI for ART in re-
cent years. Kourtis et al. [25] had found that use of PI in
ART may increase the risk of PTD compared with ART
without PI. And different initiation time of ART have
different influences on the risk of PTD. Townsend et al.
[26] also indicated that HARRT was associated with
PTD. We have ever tried to analyze the data by the
information of ART regimens, initiation time, ARVs dur-
ation, etc., however, there were not enough information
to support the analysis of the data after stratification, for
the information of ART were not provided or not de-
tailed described in all articles. Thus we could not know if
there any influences of different ART regimens or differ-
ent initiation time on the association between maternal
HIV infection and LBW/PTD. On the other hand, ARVs
might be responsible for adverse pregnancy outcomes
such as LBW and PTD, but its high effectiveness in the
prevention for mother to child transmission outweighed
its risk of LBW/PTD suggested by Santini et al. [27].
Maternal HIV infection was found to be related with
both LBW and PTD in some places such as Africa and
America. Moreover, no difference in the relationship was
detected among the different study periods. This, to a
certain degree, reflected the non-ideal treatment and
health care development in reducing the risk of LBW and
PTD for HIV infected women. So we look forward to find-
ing new regimens or methods combined with other mea-
surements like perinatal health care for pregnant women
to decrease the risk of adverse pregnancy outcomes.
Table 2 Results of subgroup analysis
Factors Groups Low birth weight Preterm delivery
No. of studies OR (95 % CI) P I2 (%) No. of studies OR (95 % CI) P I2
Design type Prospective 27 1.93(1.64, 2.28) <0.001 75.8 23 1.60(1.39, 1.84) <0.001 59.8
Retrospective 16 2.05(1.72, 2.45) <0.001 62.2 17 1.67(1.49, 1.86) <0.001 39.5
Study period Before 1995 15 1.90(1.61, 2.25) <0.001 54.4 15 1.59(1.31, 1.93) <0.001 41.2
1995–2004 14 1.72(1.42, 2.08) <0.001 63.1 15 1.55(1.34, 1.80) <0.001 66.1
2005–2015 14 2.52(1.90, 3.33) <0.001 83.7 10 1.79(1.55, 2.06) <0.001 37.9
Study location Africa 24 2.18(1.84, 2.59) <0.001 73.5 19 1.56(1.40, 1.75) <0.001 52.6
America 11 1.80(1.49, 2.19) <0.001 73.1 11 1.69(1.53, 1.88) <0.001 6.2
Europe 2 1.34(0.90, 2.00)a, 0.15 0 5 1.40(0.73, 2.68)a 0.32 80.4
Asia 6 1.99(1.05, 3.74) 0.03 77.3 5 1.60(1.10, 2.35) 0.02 27.3
Country economic Developing 31 2.12(1.81, 2.48) <0.001 72.5 26 1.60(1.44, 1.76) <0.001 48.9
Developed 12 1.75(1.44, 2.12) <0.001 71.9 14 1.67(1.41, 1.98) <0.001 52.5
ARVs exposure No 10 1.75(1.42, 2.17) <0.001 51.7 9 1.54(1.23, 1.92) <0.001 44.5
Not stated 17 2.07(1.78, 2.42) <0.001 51.2 17 1.55(1.32, 1.82) <0.001 56.2
Yes 16 2.04(1.61, 2.57) <0.001 82.1 14 1.77(1.55, 2.02) <0.001 52.4
Overall 43 1.98(1.76, 2.23) <0.001 71.7 40 1.62(1.49, 1.77) <0.001 51.8
No number, CI confidence interval, ARVs antiretroviral drugs, OR odds ratio
aNo significant difference/no statistical significance (P > 0.05)
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There are several limitations to note. Our meta-
analysis dataset was not complete due to some restric-
tions of accessing to full texts. Another limitation is that
we could not determine if maternal HIV infection had
direct effects on LBW/PTD. We could not rule out the
possibility that the association is secondary to HIV-
associated deficiency, for example maternal nutrition de-
ficiency, or other risk factors of adverse pregnancy, such
as drug use, smoking, etc. And we could not get the
association between maternal HIV infection and LBW/
PTD after controlling for different clinical stages of HIV
infection in this analysis because of the absence of such
information. The relationship between maternal HIV
infection and LBW/PTD is likely affected by the clinical
stage of HIV infection. Study conducted by Coley et al. in
Tanzania [28] indicated that although HIV infected
asymptomatic women did not have a higher risk of having
LBW infants compared with uninfected women (OR =
1.25; 95 % CI: 0.88, 1.79), symptomatic HIV-infected
women who were in Stage 2 or higher according to the
WHO staging system had about 2-time higher risks for
low birth weight (RR = 2.29; 95 % CI:1.34, 3.92) and pre-
maturity (RR = 1.93; 95 % CI: 1.35, 2.77) compared with
HIV-uninfected ones. This is consistent with the finding
of Bucceri et al. [11] and Muhangi et al. [29]. Publication
bias is always a concern for systematic reviews. Publica-
tion bias in this meta-analysis was analyzed by using
funnel plot and the Begg’s and Egger’s test methods. Sig-
nificant publication bias was detected among studies of
LBW and proper adjustment was conducted. And we
found the results of this analysis had good stability by sen-
sitivity analysis.
Conclusions
In conclusion, the findings of this study indicated that
maternal HIV infection was associated with increased
risks of both low birth weight and preterm delivery.
However, the associations were moderate. No difference
in the relationships between maternal HIV infection and
adverse pregnancy outcomes was detected among differ-
ent study periods. ARVs were not found to decrease
risks of either low birth weight or preterm delivery asso-
ciated with maternal HIV exposure.
Additional files
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delivery. (TIFF 127 kb)
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